摘要
目的观察培美曲塞(PEM)联合顺铂(DDP)方案一线治疗晚期肺腺癌的临床疗效和不良反应,并与吉西他滨(GEM)联合DDP方案相比较。方法回顾性分析我院2010年5月～2011年12月收治的64例初治晚期肺腺癌患者,将其分成两组,PEM组(34例)和GEM组(30例)分别接受PEM联合DDP方案和GEM联合DDP方案化疗,两方案均以21 d为1个周期。每例至少完成2个疗程后评价疗效及毒副反应。结果 PEM组总有效率(ORR)为85.1%,中位生存期(OS)为45周,疾病进展时间(TTP)为36周;GEM组ORR为63.3%,OS为29周,TTP为25周;PEM组ORR、TTP、OS均要优于GEM组,差异有统计学意义(P<0.05)。毒副作用方面,PEM组骨髓抑制尤其是血小板的下降明显低于GEM组,差异有统计学意义(P<0.05)。结论 PEM联合DDP一线治疗晚期肺腺癌疗效好,毒副作用轻,治疗耐受性好,是较为理想的化疗方案。
Objective To observe the clinical curative effect and adverse reactions on Pemetrexed（PEM） combined with Cisplatin（DDP） as the first-line treatment of advanced lung adenocarcinoma,and Gemcitabine（GEM） combined with DDP schemes are compared with it.Methods The advanced lung adenocarcinoma patients of first treatment were divided into two groups,PEM group（34 cases） and GEM group（30 cases）,the two groups accepted treatment of PEM combined with DDP,and GEM combined with DDP respectively,the two methods took 21 d for a cycle.Every example completed at least two course,then the therapeutic and adverse reactions were evaluated.Results In PEM group,total effectiveness（ORR） was 85.1%,median survival（OS） was 45 weeks,disease progress（TTP） was 36 weeks;in GEM group,ORR was 63.3%,OS was 29 weeks,TTP was 25 weeks;the ORR,TTP and OS in PEM group were superior to the GEM group,the differences were statistically significant（P〈0.05）.As for side effects,the bone marrow inhibit especially platelet down of PEM group was significantly lower than the GEM group,the difference was statistically significant（P〈0.05）.Conclusion PEM combined with DDP as the first-line treatment of advanced lung adenocarcinoma has a good curative effect,side effects are light,the treatment of tolerance is good,it is an ideal chemotherapy.
出处
《中国医药导报》
CAS
2012年第32期102-103,108,共3页
China Medical Herald
关键词
肺腺癌
化疗
培美曲塞
吉西他滨
顺铂
Lung adenocarcinoma
Chemotherapy
Pemetrexed
Gemcitabine
Cisplatin
